Readressing the rationale of irradiation in stage I seminoma guidelines: a critical essay

Berghen, Charlien; Albersen, Maarten; Blanchard, Pierre; Bossi, Alberto; Briganti, Alberto; Cozzarini, C.; Decaestecker, Karel; Fonteyne, Valérie; Haustermans, Karin; Joniau, Steven; Joon, Daryl Lim; Khoo, Vincent; Nguyen, Paul L.; Ost, Piet; Villeirs, Geert; Vulsteke, Christof; Zietman, Anthony L.; Meerleer, Gert De

doi:10.1111/bju.14686

Cited by 5 publications

(3 citation statements)

References 45 publications

(68 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…9,24-28 However, this observed higher risk of secondary malignancies must be viewed critically, as radiation dose, treatment volume and technique have improved remarkably since publication of the above cited studies. 14,26 Treatment field and dose reduction, and improvements in dose planning have demonstrated to significantly reduce the incidence of secondary malignancies. [29][30][31] Because the TE18 trial showed the noninferiority of 20 Gy compared with 30 Gy, the recommended radiation dose for CS I is now 20 Gy in 10 fractions applied in a para-aortic strip field.…”

Section: Discussionmentioning

confidence: 99%

Patterns of Disease Progression and Outcome of Patients With Testicular Seminoma Who Relapse After Adjuvant or Curative Radiation Therapy

Terbuch

Posch

Bauernhofer

et al. 2022

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Patterns of Disease Progression and Outcome of Patients With Testicular Seminoma Who Relapse After Adjuvant or Curative Radiation Therapy

Terbuch

Posch

Bauernhofer

et al. 2022

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

“…As a result, radiation therapy as an adjuvant treatment for stage I seminoma has declined in recent years. [10][11][12] According to research by Powles and colleagues, there was a nonsignificant increase in mortality over a period of nine years following the administration of carboplatin in the context of ischemic heart disease and cerebrovascular events. 13 Additionally, they could not confirm the lower incidence of secondary cancers, which is often considered a benefit of chemotherapy compared to radiation therapy.…”

Section: Resultsmentioning

confidence: 99%

Untitled

2023

JCPCR

View full text Add to dashboard Cite

show abstract

“…As shown in recent studies, radiotherapy was significantly associated with severe side effects; therefore, the use of RT has been criticized 13. As shown in the study by Maroto et al,14 the risk of a second solid non-germ-cell tumor is approximately doubled after radiotherapy or chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

<p>Clinical characteristics of testicular seminoma in individuals in West China: a 10-year follow-up study</p>

Chen

Qiu

Cao

et al. 2019

CMAR

View full text Add to dashboard Cite

Objective To assess the clinical characteristics of testicular seminoma (TS). Patients and methods A testicular cancer (TC) survey was conducted by the Department of Urology, West China Hospital, between 2008 and 2018. Tumors were classified according to the NCCN criteria such as age, tumor size, tumor marker levels, histopathology, clinical stage, initial treatment, follow-up, and clinical outcomes, were obtained from the database of our center. Results Among 155 registered cases of TC with seminomatous element, 127 cases of pure TS were analyzed. All 127 patients with a median age of 37 years were pathologically diagnosed with orchiectomy specimens. Orchiectomy, chemotherapy, and radiotherapy were the main treatments for these patients. Patients with clinical stages I, II, and III testicular cancer of accounted for 81.1% (n=103), 15.7% (n=20), and 3.2% (n=4) of all patients, respectively. After a median follow-up time of 50 months, five patients presented with relapse during follow-up, and one among them died. Of the patients with stage I TS (T1N0M0S0 CS IA), three patients who only underwent orchiectomy relapsed. Among patients with stage II TS (T1N1M0S1 CS IIA), one patient relapsed after orchiectomy, post-surgery chemotherapy and radiotherapy. In four patients with stage III disease (T2N1M1aS1 CS IIIA), one relapsed after orchiectomy and chemotherapy, and died shortly after salvage chemotherapy and radiotherapy due to recurrence. The median overall survival time was 50 months. In all patients, the 2-year overall survival and progression-free survival probabilitis were 98.6% and 98.8%, respectively. Conclusion The present study shows that patients with TS have good prognosis even at an advanced stage. Surveillance after orchiectomy was important for patients with CSI seminoma, and we recommend cisplatin-based chemotherapy as salvage therapy for patients with CSI seminoma. In addition, patients with a maximal tumor diameter >4 cm should undergo post-surgery chemotherapy.

show abstract

Readressing the rationale of irradiation in stage I seminoma guidelines: a critical essay

Cited by 5 publications

References 45 publications

Patterns of Disease Progression and Outcome of Patients With Testicular Seminoma Who Relapse After Adjuvant or Curative Radiation Therapy

Patterns of Disease Progression and Outcome of Patients With Testicular Seminoma Who Relapse After Adjuvant or Curative Radiation Therapy

Untitled

<p>Clinical characteristics of testicular seminoma in individuals in West China: a 10-year follow-up study</p>

Contact Info

Product

Resources

About